|
1
|
World Health Organization: Launch of
SOLIDARITY trial (press release). Accessed March 18, 2020.
|
|
2
|
INSERM: Launch of a European clinical
trial against COVID-19 (press release). Accessed March 22,
2020.
|
|
3
|
Kupferschmidt K and Cohen J: Race to find
COVID-19 treatments accelerates. Science. 367:1412–1413.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. doi: 10.1001/jama.2020.1585.
2020.[Epub ahead of print]. PubMed/NCBI View Article : Google Scholar
|
|
7
|
Andersen KG, Rambaut A, Lipkin WI, Holmes
EC and Garry RF: The proximal origin of SARS-CoV-2. Nat Med.
26:450–452. 2020.
|
|
8
|
Sheahan TP, Sims AC, Graham RL, Menachery
VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I,
et al: Broad-spectrum antiviral GS-5734 inhibits both epidemic and
zoonotic coronaviruses. Sci Transl Med. 9(pii:
eaal3653)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu
M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 30:269–271. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Agostini ML, Andres EL, Sims AC, Graham
RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, et al:
Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is
mediated by the viral polymerase and the proofreading
exoribonuclease. mBio. 9(pii: e00221-18)2018. View Article : Google Scholar
|
|
11
|
Grein J, Ohmagari N, Shin D, Diaz G,
Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et
al: Compassionate use of remdesivir for patients with severe
Covid-19. N Engl J Med. doi: 10.1056/NEJMoa2007016. 2020.[Epub
ahead of print]. PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181(271-280.e8)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rainsford KD, Parke AL, Clifford-Rashotte
M and Kean WF: Therapy and pharmacological properties of
hydroxychloroquine and chloroquine in treatment of systemic lupus
erythematosus, rheumatoid arthritis and related diseases.
Inflammopharmacology. 23:231–269. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen Z, Hu J and Zhang Z, Jiang S, Han S,
Yan D, Zhuang R, Hu B and Zhang Z: Efficacy of hydroxychloroquine
in patients with COVID-19: Results of a randomized clinical trial.
medRxiv. doi: 2020.03.22.20040758. 2020.
|
|
15
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2020.105949.
2020.[Epub ahead of print]. PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sheahan TP, Sims AC, Leist SR, Schäfer A,
Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et
al: Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat
Commun. 11(222)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Baden LR and Rubin EJ: Covid-19 - The
search for effective therapy. N Engl J Med. doi:
10.1056/NEJMe2005477. 2020.[Epub ahead of print]. PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A trial of
lopinavir-ritonavir in adults hospitalized with severe Covid-19. N
Engl J Med. doi: 10.1056/NEJMoa2001282. 2020.[Epub ahead of print].
PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dong L, Hu S and Gao J: Discovering drugs
to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther.
14:58–60. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen C, Zhang Y, Huang J, Yin P, Cheng Z,
Wu J, Chen S, Zhang Y, Chen B, Lu M, et al: Favipiravir versus
arbidol for COVID-19: a randomized clinical trial. medRxiv. doi:
2020.03.17.20037432. 2020.
|
|
21
|
uriClinicalTrials.govsimpleClinicalTrials.gov. Various
combination of protease inhibitors oseltamivir favipiravir
hydroxychloroquine for treatment of COVID-19: a randomized control
trial (THDMS-COVID-19). https://clinicaltrials.gov/ct2/show/NCT04303299,
2020.
|
|
22
|
uriClinicalTrials.govsimpleClinicalTrials.gov.
Favipiravir combined with tocilizumab in the treatment of corona
virus disease. https://clinicaltrials.gov/ct2/show/NCT04310228,
2020.
|
|
23
|
Newswire PR: Sihuan pharmaceutical
announces clinical research of favipiravir, co-developed with the
Academy of Military Medical Sciences of the People's Liberation
Army, has commenced. Sihuan Pharmaceutical Holdings Group Ltd,
2020. https://en.prnasia.com/releases/apac/sihuan-pharmaceutical-announces-clinical-research-of-favipiravir-co-developed-with-the-academy-of-military-medical-sciences-of-the-people-s-liberation-army-has-commenced-273880.shtml.
|
|
24
|
Sheahan TP, Sims AC, Zhou S, Graham RL,
Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH III,
Stevens LJ, et al: An orally bioavailable broad-spectrum antiviral
inhibits SARS-CoV-2 in human airway epithelial cell cultures and
multiple coronaviruses in mice. Sci Transl Med. (pii:
eabb5883)2020. View Article : Google Scholar
|
|
25
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersall RS and Manson JJ: HLH Across Speciality Collaboration,
UK: COVID-19: consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ritchie AI and Singanayagam A:
Immunosuppression for hyperinflammation in COVID-19: a double-edged
sword? Lancet. 395(1111)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Alhazzani W, Møller MH, Arabi YM, Loeb M,
Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, et al:
Surviving sepsis campaign: guidelines on the management of
critically ill adults with coronavirus disease 2019 (COVID-19).
Crit Care Med. doi: 10.1097/CCM.0000000000004363. 2020.[Epub ahead
of print]. View Article : Google Scholar
|
|
28
|
Poston JT, Patel BK and Davis AM:
Management of critically ill adults with COVID-19. JAMA. doi:
10.1001/jama.2020.4914. 2020.[Epub ahead of print]. View Article : Google Scholar
|
|
29
|
Ferioli M, Cisternino C, Leo V, Pisani L,
Palange P and Nava S: Protecting healthcare workers from SARS-CoV-2
infection: practical indications. Eur Respir Rev. 29(pii:
200068)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Molina JM, Delaugerre C, Le Goff J,
Mela-Lima B, Ponscarme D, Goldwirt L and De Castro N: No evidence
of rapid antiviral clearance or clinical benefit with the
combination of hydroxychloroquine and azithromycin in patients with
severe COVID-19 infection. Med Mal Infect. (pii:
S0399-077X(20)30085-8)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Taccone FS, Gorham J and Vincent JL:
Hydroxychloroquine in the management of critically ill patients
with COVID-19: the need for an evidence base. Lancet Respir Med.
pii(S2213-2600(20)30172-7)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kaly L and Rosner I: Tocilizumab - a novel
therapy for non-organ-specific autoimmune diseases. Best Pract Res
Clin Rheumatol. 26:157–165. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xu X, Han M, Li T, Sun W, Wang D, Fu B,
Zhou Y, Zheng X, Yang Y, Li X, et al: Effective treatment of severe
COVID-19 patients with tocilizumab. ChinaXiv preprint.
2020.chinaXiv:202003.00026v1: View Article : Google Scholar
|
|
34
|
uriClinicalTrials.govsimpleClinicalTrials.gov. A study
to evaluate the safety and efficacy of tocilizumab in patients with
severe COVID-19 pneumonia (COVACTA). https://clinicaltrials.gov/ct2/show/NCT04320615,
2020.
|
|
35
|
Atluri S, Manchikanti L and Hirsch JA:
Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a
therapeutic strategy in mnaging critically III COVID-19 patients:
the case for compassionate use. Pain Physician.
(E71-E83)2020.PubMed/NCBI
|
|
36
|
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han
Q, Shan G, Meng F, Du D, Wang S, et al: Transplantation of ACE2(-)
mesenchymal stem cells improves the outcome of ptients with
COVID-19 pneumonia. Aging Dis. 11:216–228. 2020.PubMed/NCBI View Article : Google Scholar
|
